Searchable abstracts of presentations at key conferences in endocrinology

ea0037mte7 | (1) | ECE2015

Management of adrenal insufficiency

Hahner Stefanie

For a long time it has been assumed that patients with adrenal insufficiency (AI) can live without any restriction when receiving standard hormone replacement therapy.However, recent evidence indicates that subjective health status (SHS) in patients with primary adrenal insufficiency is significantly impaired at least in a subgroup of patients and that mortality is increased compared to the general population.The observation of imp...

ea0026s7.3 | Novel approaches to <emphasis role="italic">in vitro</emphasis> and <emphasis role="italic">in vivo</emphasis> imaging | ECE2011

Molecular and clinical imaging of adrenal steroidogenesis by iodometomidate

Hahner Stefanie

Molecular imaging technologies are emerging tools providing both researchers and clinicians with technologies for non invasive in vivo studies. Steroidogenic enzymes are abundantly and specifically expressed in steroidogenic tissue and represent an interesting target for tissue specific characterization. Iodometomidate is a highly potent inhibitor of cortisol and aldosterone synthesis due to specific and high affinity binding to both CYP11B1- and CYP11B2-enzymes. Our ai...

ea0021cm3.4 | Management of congenital adrenal hyperplasia across the lifespan | SFEBES2009

Quality of life in CAH: does it differ from adrenal insufficiency?

Hahner Stefanie

Quality of life (QoL) is significantly impaired in patients with primary and secondary adrenal insufficiency (AI) irrespective of the glucocorticoid dosing regimen or the currently available glucocorticoid preparation. The impairment of QoL has been particularly attributed to the unphysiological mode of glucocorticoid replacement, which only roughly resembles the physiological profile. In both congenital adrenal hyperplasia (CAH) and Addison's disease, failure in cortisol synt...

ea0081p762 | Late-Breaking | ECE2022

Do polymorphisms of the glucocorticoid and mineralocorticoid receptors play a role in adrenal crises?

Chifu Irina , Janik Freytag , Herterich Sabine , Heike Weber , Hahner Stefanie

Introduction: Polymorphisms of the glucocorticoid (NR3C1) and mineralocorticoid receptor (NR3C2) have been linked to the regulation of HPA-axis and to glucocorticoid sensitivity. We investigated whether NR3C1 and NR3C2 polymorphisms correlate with the occurence of adrenal crises (AC) in patients with primary adrenal insufficiency (PAI).Material and methods: We investigated 100 patients with PAI (70% women, mean age 51±15 years). DNA was extracted fr...

ea0038p407 | Steroids | SFEBES2015

Conventional vs modified release hydrocortisone in mitotane treated patients with adrenocortical cancer

Weigel Marianne , Hahner Stefanie , Beier Daniela , Zopf Kathrin , Quinkler Marcus

Background: Mitotane is a strong inducer of hepatic CYP3A4 activity (cortisol metabolism) and increases cortisol-binding globulin (CBG). High hydrocortisone dosages are necessary in patients with adrenocortical cancer (ACC) on mitotane treatment. The newly modified release hydrocortisone has not been used in mitotane-treated ACC patients yet.Aim: To compare cortisol (serum and saliva), calculated free serum cortisol and ACTH levels in ACC patients on mit...

ea0020s23.4 | Adrenocortical tumours – pathogenesis and management | ECE2009

Chemotherapy and radiotherapy for adrenocortical carcinoma (ACC)

Fassnacht Martin , Hahner Stefanie , Polat Buelent , Allolio Bruno

ACC is a rare, heterogeneous malignancy with poor prognosis. Data from the German ACC Registry (n=478) indicate a 5-year survival rate of 47%. In addition to mitotane, cytotoxic drugs are standard of care in advanced ACC. The best results have been reported by Berruti et al. for the combination of mitotane with etoposide, doxorubicin and cisplatin with an objective tumor response rate of 49% in 72 patients. A response rate of 36% was published for the combination...

ea0081rc2.2 | Rapid Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022

FKBP5 methylation in adrenal insufficiency: looking at a new tool for assessing the quality of glucocorticoid replacement?

Chifu Irina , Carolin Scheuermann , Stephanie Burger-Stritt , Lippert Juliane , Herterich Sabine , Hahner Stefanie

Available glucocorticoid (GC) replacement regimens in adrenal insufficiency (AI) only roughly correspond to physiological steroid profiles. Control of substitution quality is therefore difficult but significant, as even mild chronic over- or under-replacement may be clinically relevant. FKBP5 regulates GC receptor sensitivity by reducing its affinity to cortisol when bound to the receptor complex. FKBP5 methylation has been inversely correlated with cortisol levels both in hea...

ea0041ep15 | Adrenal cortex (to include Cushing's) | ECE2016

Impact of the chemokine receptors CXCR4 and CXCR7 on metastatic potential and survival in adrenocortical carcinoma

Chifu Irina , Fusz Carmina , Ronchi Cristina , Marienfeld Katja , Fassnacht Martin , Hahner Stefanie , Heinze Britta

Background: The chemokine receptor CXCR4 and its associate receptor CXCR7, that modulates CXCR4 function, have been associated with tumor progression and metastasis in human cancers. In ACC, Ki67 index and ENSAT stage are the most important prognostic parameters.Objective: To assess expression of CXCR4 and CXCR7 in adrenal cancer and correlate results with clinical outcome.Methods: CR expression was assessed by immunohistochemistry...

ea0070aep152 | Bone and Calcium | ECE2020

Renal complications in chronic hypoparathyroidism – a german single-center analysis in 169 patients

Gronemeyer Karen , Teresa Fuss Carmina , Hermes Franca , Plass Armin , Koschker Ann-Cathrin , Hahner Stefanie

Introduction: Although long-term complications such as nephrocalcinosis and renal insufficiency are well-known in chronic hypoparathyroidism (HPT), standardized investigations of their prevalence and causes are still lacking.Objective: To systematically investigate the prevalence of renal calcifications and dysfunction and their predictors in a well-characterized cohort of patients with HPT.Methods: Cross-sectional assessment of co...

ea0070aep154 | Bone and Calcium | ECE2020

Psychiatric Comorbidities in Chronic Hypoparathyroidism – a German Single-Center Analysis in 107 Patients

Teresa Fuss Carmina , Hermes Franca , Koschker Ann-Cathrin , Unterecker Stefan , Deckert Jürgen , Hahner Stefanie

Introduction: Reduction of quality of life in patients with chronic hypoparathyroidism (HPT) has been reported by several studies. Additionally, self-report data point to a higher prevalence of anxiety disorders in HPT compared to patients after thyroidectomy.Objectives: To characterize psychiatric diseases in a systematically reviewed cohort of patients with chronic HPT.Methods: We systematically assessed psychiatric comorbidities...